Skip to main content

Peer Review reports

From: Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

Original Submission
23 Aug 2018 Submitted Original manuscript
31 Aug 2018 Author responded Author comments - Iben Kümler
Resubmission - Version 2
31 Aug 2018 Submitted Manuscript version 2
14 Nov 2018 Reviewed Reviewer Report - Reham Abdel-Wahab
13 Apr 2019 Reviewed Reviewer Report - Peter Kern
13 May 2019 Author responded Author comments - Iben Kümler
Resubmission - Version 3
13 May 2019 Submitted Manuscript version 3
Publishing
31 May 2019 Editorially accepted
13 Jun 2019 Article published 10.1186/s12885-019-5788-9

You can find further information about peer review here.

Back to article page